AR099523A1 - Compuestos derivados de 6,7-dihidro-3h-oxazolo[3,4-a]pirazina-5,8-diona - Google Patents

Compuestos derivados de 6,7-dihidro-3h-oxazolo[3,4-a]pirazina-5,8-diona

Info

Publication number
AR099523A1
AR099523A1 ARP150100529A ARP150100529A AR099523A1 AR 099523 A1 AR099523 A1 AR 099523A1 AR P150100529 A ARP150100529 A AR P150100529A AR P150100529 A ARP150100529 A AR P150100529A AR 099523 A1 AR099523 A1 AR 099523A1
Authority
AR
Argentina
Prior art keywords
phenyl
benzyl
salts
prop
butyl
Prior art date
Application number
ARP150100529A
Other languages
English (en)
Original Assignee
Biolab Sanus Farmacêutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolab Sanus Farmacêutica Ltda filed Critical Biolab Sanus Farmacêutica Ltda
Publication of AR099523A1 publication Critical patent/AR099523A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La presente se refiere a compuestos o a una mezcla de éstos, composiciones farmacéuticas que comprendan una cantidad eficaz de uno de los compuestos, así como el uso de dichos compuestos y/o derivados como inhibidores de enzimas fosfodiesterasas y el uso de los compuestos y/o derivados en el tratamiento de la disfunción eréctil, de trastornos y/o condiciones tratables con relajación de tejidos y de trastornos tratables con inhibidores de fosfodiesterasas, más específicamente con inhibidores de la PDE-5. Reivindicación 1: Un compuesto derivado de 6,7-dihidro-3H-oxazolo[3,4-a]pirazina-5,8-diona, caracterizado por presentar la fórmula (1) en la que: R¹ es un grupo aromático, un grupo aromático con uno o más heteroátomos, grupos fenilo, fenol, 3-metoxi-4-fenol, 3,4-metilen-dioxifenilo, 2-metoxifenilo, 3-metoxifenilo, 4-metoxifenilo, 3,4-dimetoxifenilo, 2-halo-fenilo, 3-halo-fenilo, 4-halo-fenilo, furilo; piridínico, aromático bicíclico, aromático bicíclico con uno o más heteroátomos; R² es arilo, heteroarilo, bicicloarilo, CH₂(CH₂)ₙR³, CH₂(CH₂)ₙNR⁴R⁵, CHR⁶CH₂OH, CH₂CH(OH)R⁷, CH₂(CH₂)OR⁸, CH₂(CH₂)ₙSR⁹, sales de carboxilato, sales de sulfonato o sales de amonio cuaternario; R³ es OH, NH₂, NH₃⁺, S(O)Me, SO₃H, CO₂H, Cl, sales de carboxilato, sales de sulfonato o sales de amonio cuaternario; R⁴ es hidrógeno, metilo, etilo, propilo, i-propilo, butilo, sec-butilo, terc-butilo ,fenilo, bencilo o sales de amonio cuaternario; R⁵ es hidrógeno, metilo, etilo, propilo, i-propilo, butilo, sec-butilo, terc-butilo, fenilo, bencilo o sales de amonio cuaternario; R⁶ es (R)-Me, (R)-Et, (R)-i-Prop, (R)-i-But, (R)-fenil, (R)-CH₂SH, (R)-CH₂CH₂SCH₃, (R)-bencilo, (R)-sec-But, (S)-Me, (S)-Et, (S)-i-Prop, (S)-i-But, (S)-fenilo, (S)-CH₂SH, (S)-CH₂CH₂SCH₃, (S)-bencilo, (S)-sec-But ó CH₂OH; R⁷ es (R)-Me, (R)-Et; (R)-Prop, (R)-i-Prop, (R)-fenil, (R)-bencilo, (S)-Me, (S)-Et; (S)-Prop, (S)-i-Prop, (S)-fenilo o (S)-bencilo; R⁸ es C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, fenilo o bencilo; R⁹ es C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, fenilo o bencilo; n es un número comprendido entre 0 y 4; la mezcla de dichos derivados, sus sales, solvatos, hidratos, profármacos y ésteres farmacéuticamente aceptables; así como sus enantiómeros y/o diastereoisómeros en sus formas individuales separadas y/o en las formas de mezclas racémicas o mezclas no racémicas con exceso enantiomérico en cualquier proporción.
ARP150100529A 2014-02-24 2015-02-23 Compuestos derivados de 6,7-dihidro-3h-oxazolo[3,4-a]pirazina-5,8-diona AR099523A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461943825P 2014-02-24 2014-02-24

Publications (1)

Publication Number Publication Date
AR099523A1 true AR099523A1 (es) 2016-07-27

Family

ID=53877456

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100529A AR099523A1 (es) 2014-02-24 2015-02-23 Compuestos derivados de 6,7-dihidro-3h-oxazolo[3,4-a]pirazina-5,8-diona

Country Status (19)

Country Link
US (1) US9359378B2 (es)
EP (1) EP3133072B1 (es)
JP (1) JP6636463B2 (es)
KR (1) KR102408431B1 (es)
AR (1) AR099523A1 (es)
AU (1) AU2015221431B2 (es)
BR (1) BR112016019609B1 (es)
CA (1) CA2940225C (es)
CL (1) CL2016002125A1 (es)
ES (1) ES2734063T3 (es)
HU (1) HUE044993T2 (es)
IL (1) IL247330B (es)
MX (1) MX369840B (es)
PL (1) PL3133072T3 (es)
PT (1) PT3133072T (es)
TR (1) TR201910896T4 (es)
UY (1) UY36010A (es)
WO (1) WO2015123748A1 (es)
ZA (1) ZA201606522B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021015425A (es) * 2019-07-15 2022-02-21 Biolab Sanus Farmaceutica Ltda Estereoisomeros del compuesto 3-(benzo[d][1,3]dioxol-5-il)-7-(1-hi droxipropano-2-il)-1-(1h-indol-3-il)-6,7-dihidro-3h-oxazol[3,4-a] pirazina-5,8-diona y su uso como antitumoral y inhibidor de la enzima fosfodiesterasa.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098877A1 (en) * 2001-06-05 2002-12-12 Lilly Icos Llc Pyrazino 1',2':1,6 pyrido 3,4-b indole1,4-dione derivatives
AR045950A1 (es) * 2003-10-09 2005-11-16 Speedel Experimenta Ag Compuestos derivados de piperazina, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
AR073522A1 (es) * 2008-09-30 2010-11-10 Biolab Sanus Farmaceutica Ltda Compuestos derivados de 2-(3-metilenodioxi) - benzoil indol
BRPI0903803B1 (pt) * 2009-09-30 2019-07-09 Biolab Sanus Farmacêutica Ltda. Composto, processo de preparação, composição farmacêutica e uso dos compostos
UY33535A (es) * 2010-08-13 2011-12-01 Biolab Sanus Farmaceutuca Limitada Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona

Also Published As

Publication number Publication date
TR201910896T4 (tr) 2019-08-21
AU2015221431A8 (en) 2016-11-24
EP3133072A4 (en) 2017-08-09
HUE044993T2 (hu) 2019-11-28
ZA201606522B (en) 2018-04-25
JP6636463B2 (ja) 2020-01-29
CL2016002125A1 (es) 2016-12-30
MX369840B (es) 2019-11-22
AU2015221431B2 (en) 2018-04-19
IL247330B (en) 2020-10-29
CA2940225A1 (en) 2015-08-27
PL3133072T3 (pl) 2019-10-31
KR102408431B1 (ko) 2022-06-13
MX2016010912A (es) 2016-11-30
IL247330A0 (en) 2016-09-29
EP3133072B1 (en) 2019-05-01
JP2017506263A (ja) 2017-03-02
CA2940225C (en) 2021-12-28
US9359378B2 (en) 2016-06-07
PT3133072T (pt) 2019-07-26
KR20160116028A (ko) 2016-10-06
AU2015221431A1 (en) 2016-09-29
US20150239903A1 (en) 2015-08-27
ES2734063T3 (es) 2019-12-04
WO2015123748A1 (pt) 2015-08-27
BR112016019609B1 (pt) 2022-06-14
EP3133072A1 (en) 2017-02-22
UY36010A (es) 2015-09-30
BR112016019609A2 (es) 2017-08-22

Similar Documents

Publication Publication Date Title
AR097431A1 (es) Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
AR085004A1 (es) Inhibidores selectivos de glicosidasas y usos de los mismos
PE20181024A1 (es) Derivados de ciclohexano sustituido con amido
CU20100229A7 (es) Compuestos triazina como inhibidores mtor y quinasa p13
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
CR20150371A (es) Inhibidores de prmt5 y sus usos
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
PE20190339A1 (es) 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1
AR087913A1 (es) Inhibidores sustituidos de n-[1-ciano-2-(fenil)etil]-2-azabiciclo[2,2,1]heptan-3-carboxamida de catepsina c
AR070136A1 (es) Pirimidil ciclopentanos como inhibidores de la akt proteina quinasa
AR063723A1 (es) 5-oxo-5,8-dihidro-piridopirimidinas inhibidoras de c-fms quinasas, composiciones farmaceuticas que las contienen y usos como agentes anticancer, en enfermedades cardiovasculares y procesos inflamatorios
PE20160885A1 (es) Derivados de purina 2,6 sustituidos en el tratamiento de transtornos proliferativos
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
CO7111275A2 (es) Inhibidores de dgat1 de éter cíclico de cabeza de puente
PE20181853A1 (es) 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1
AR102544A1 (es) Compuestos derivados de dihidrohidantoína como herbicidas
AR068466A1 (es) Cianoisoquinolina
AR070188A1 (es) Derivados de sulfonamidas sustituidas
AR101964A1 (es) Compuestos de imidazopiridazina como moduladores de pi3k
AR100713A1 (es) Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor
AR080871A1 (es) Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa
CO6362013A2 (es) Derivados de rifamicina
AR100776A1 (es) Compuestos herbicidas
CU20160148A7 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2
CO2021001217A2 (es) Inhibidores tipo indol y azaindol de enzimas pad

Legal Events

Date Code Title Description
FG Grant, registration